History Founded in 1997 based on research at the Norwegian Cancer Hospital. Transforming from a technology platform based company to a specialty pharma – The Bladder Cancer Company. Photocure was founded by the Norwegian Radium Hospital to develop and commercialize a promising photodynamic non-melanoma skin cancer product with a vision to become a global leader in photodynamic technology. Today Photocure is focusing on bladder cancer with the aim to deliver transformative solutions to improve the lives of bladder cancer patients. We operate in Europe and the U.S. with approximately 100 highly skilled employees and through partners in other territories. 2021 Hexvix® licensed to Asieris Meditech Co. Ltd for Mainland China & Taiwan Photocure opens its European Head Office in Düsseldorf, Germany. Regulatory approval of Hexvix® in Chile 2020 Photocure retrieves the rights to commercialize Hexvix® in European markets, from Ipsen. Genotests SpA appointed as exclusive partner for Hexvix in Chile 2019 Cevira® out-licensed to Asieris Meditech Co., Ltd 2018 New CEO appointed - Dan Schneider FDA Approval of expanded Indications for Blue Light Cystoscopy with Cysview® Starting exclusive Nordic distribution of HIVEC® for Combat Medical 2017 Photocure files supplemental New Drug Application with FDA for Blue Light Cystoscopy (BLC®) with Cysview® Allumera® divested to Bellus 2016 Blue light cystoscopy with Hexvix®/Cysview® recommended in the new AUA/SUO guidelines Hexvix® marketing authorization approval in Australia Hexvix® granted EU approval for prefilled syringe product packaging 2015 Hexvix® licensed by Juno Pharmaceuticals in Australia and New Zealand Cysview® licensed by BioSyent Pharma in Canada Hexvix® recommended in NICE Guidelines, UK 2014 Licensing agreement with Salix terminated 2013 Positive results of phase 2b Cevira® study 2012 Cysview® launch by Photocure in the U.S. Exit Allumera® U.S. business 2011 Allumera® launched in the U.S. Hexvix® licensed to Ipsen Pharma for all territories in the world except U.S. and Nordics 2010 Photocure Inc. established in the U.S. Lumacan® licensed to Salix Cysview® approved in the U.S. 2009 Metvix®/Aktilite® divested to Galderma S.A. 2008 Metvix®/Aktilite® approved in the U.S. PCI Biotech divested from Photocure 2008 Metvix®/Aktilite® approved in the U.S. Completion of pivotal phase III study for Cysview® U.S. submission 2006 Hexvix® licensed to GE Healthcare Hexvix® launched in the EU 2005 Hexvix® launched in the Nordics 2004 First approval for Hexvix® 2003 Galderma S.A launches Metvix®. 2002 Metvix® launched in the Nordics 2001 Metvix® licensed to Galderma S.A. First approval for Metvix® 2000 Listed in the Oslo Stock Exchange (OSE) 1997 First full-time employee Newsletter Subscribe to get the latest news when they are published Subscribe Unsubscribe Privacy policy Terms of use Follow Us Norway PHOTOCURE ASA Hoffsveien 4 0275 Oslo Norway Phone: +47 22 06 22 10 Fax: +47 22 06 22 18 Mail: info@photocure.no www.hexvix.com United States PHOTOCURE INC 104 Carnegie Center Suite 303 Princeton, NJ 08540 USA Phone: +1 609 759 6500 Fax: +1 609 799 0816 Mail: info@photocure.com www.cysview.com